Pelvic Lymphadenectomy May Not Improve Biochemical Recurrence-Free Survival in Patients with Prostate Cancer Treated with Robot-Assisted Radical Prostatectomy in Japan (The MSUG94 Group)
In this multicenter retrospective cohort study, we aimed to evaluate whether pelvic lymph node dissection (PLND) improved biochemical recurrence (BCR) in patients with prostate cancer (PCa) who underwent robot-assisted radical prostatectomy (RARP) in Japan. A multicenter retrospective cohort study o...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/23/5803 |
| _version_ | 1797463586229977088 |
|---|---|
| author | Sanae Namiki Makoto Kawase Shin Ebara Tomoyuki Tatenuma Takeshi Sasaki Yoshinori Ikehata Akinori Nakayama Masahiro Toide Tatsuaki Yoneda Kazushige Sakaguchi Jun Teishima Kazuhide Makiyama Takahiro Inoue Hiroshi Kitamura Kazutaka Saito Fumitaka Koga Shinji Urakami Takuya Koie |
| author_facet | Sanae Namiki Makoto Kawase Shin Ebara Tomoyuki Tatenuma Takeshi Sasaki Yoshinori Ikehata Akinori Nakayama Masahiro Toide Tatsuaki Yoneda Kazushige Sakaguchi Jun Teishima Kazuhide Makiyama Takahiro Inoue Hiroshi Kitamura Kazutaka Saito Fumitaka Koga Shinji Urakami Takuya Koie |
| author_sort | Sanae Namiki |
| collection | DOAJ |
| description | In this multicenter retrospective cohort study, we aimed to evaluate whether pelvic lymph node dissection (PLND) improved biochemical recurrence (BCR) in patients with prostate cancer (PCa) who underwent robot-assisted radical prostatectomy (RARP) in Japan. A multicenter retrospective cohort study of 3195 PCa patients undergoing RARP at nine institutions in Japan was conducted. Enrolled patients were divided into two groups: those who underwent RARP without PLND (non-PLND group) and those who underwent PLND (PLND group). The primary endpoint was biochemical recurrence-free survival (BRFS) in PCa patients who underwent PLND. We developed a propensity score analysis to reduce the effects of selection bias and potential confounding factors. Propensity score matching resulted in 1210 patients being enrolled in the study. The 2-year BRFS rate was 95.0% for all patients, 95.8% for the non-PLND group, and 94.3% for the PLND group (<i>p</i> = 0.855). For the all-risk group according to the National Comprehensive Cancer Network risk stratification, there were no significant differences between patients who did and did not undergo PLND. Based on the results of the log-rank study, PLND may be unnecessary for patients with PCa undergoing RARP. |
| first_indexed | 2024-03-09T17:52:51Z |
| format | Article |
| id | doaj.art-f370a4e889bc425c9549bd1e8a8139fe |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T17:52:51Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-f370a4e889bc425c9549bd1e8a8139fe2023-11-24T10:38:55ZengMDPI AGCancers2072-66942022-11-011423580310.3390/cancers14235803Pelvic Lymphadenectomy May Not Improve Biochemical Recurrence-Free Survival in Patients with Prostate Cancer Treated with Robot-Assisted Radical Prostatectomy in Japan (The MSUG94 Group)Sanae Namiki0Makoto Kawase1Shin Ebara2Tomoyuki Tatenuma3Takeshi Sasaki4Yoshinori Ikehata5Akinori Nakayama6Masahiro Toide7Tatsuaki Yoneda8Kazushige Sakaguchi9Jun Teishima10Kazuhide Makiyama11Takahiro Inoue12Hiroshi Kitamura13Kazutaka Saito14Fumitaka Koga15Shinji Urakami16Takuya Koie17Department of Urology, Gifu University Graduate School of Medicine, Gifu 5011194, JapanDepartment of Urology, Gifu University Graduate School of Medicine, Gifu 5011194, JapanDepartment of Urology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima 7308518, JapanDepartment of Urology, Yokohama City University, Yokohama 2360004, JapanDepartment of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu 5148507, JapanDepartment of Urology, University of Toyama, Toyama 9300194, JapanDepartment of Urology, Dokkyo Medical University Saitama Medical Center, Koshigaya 3438555, JapanDepartment of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo 1138677, JapanDepartment of Urology, Seirei Hamamatsu General Hospital, Hamamatsu 4308558, JapanDepartment of Urology, Toranomon Hospital, Tokyo 1058470, JapanDepartment of Urology, Kobe City Hospital Organization Kobe City Medical Center West Hospital, Kobe 6530013, JapanDepartment of Urology, Yokohama City University, Yokohama 2360004, JapanDepartment of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu 5148507, JapanDepartment of Urology, University of Toyama, Toyama 9300194, JapanDepartment of Urology, Dokkyo Medical University Saitama Medical Center, Koshigaya 3438555, JapanDepartment of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo 1138677, JapanDepartment of Urology, Toranomon Hospital, Tokyo 1058470, JapanDepartment of Urology, Gifu University Graduate School of Medicine, Gifu 5011194, JapanIn this multicenter retrospective cohort study, we aimed to evaluate whether pelvic lymph node dissection (PLND) improved biochemical recurrence (BCR) in patients with prostate cancer (PCa) who underwent robot-assisted radical prostatectomy (RARP) in Japan. A multicenter retrospective cohort study of 3195 PCa patients undergoing RARP at nine institutions in Japan was conducted. Enrolled patients were divided into two groups: those who underwent RARP without PLND (non-PLND group) and those who underwent PLND (PLND group). The primary endpoint was biochemical recurrence-free survival (BRFS) in PCa patients who underwent PLND. We developed a propensity score analysis to reduce the effects of selection bias and potential confounding factors. Propensity score matching resulted in 1210 patients being enrolled in the study. The 2-year BRFS rate was 95.0% for all patients, 95.8% for the non-PLND group, and 94.3% for the PLND group (<i>p</i> = 0.855). For the all-risk group according to the National Comprehensive Cancer Network risk stratification, there were no significant differences between patients who did and did not undergo PLND. Based on the results of the log-rank study, PLND may be unnecessary for patients with PCa undergoing RARP.https://www.mdpi.com/2072-6694/14/23/5803multicenter cohort studypelvic lymph node dissectionprostate cancerrobot-assisted radical prostatectomy |
| spellingShingle | Sanae Namiki Makoto Kawase Shin Ebara Tomoyuki Tatenuma Takeshi Sasaki Yoshinori Ikehata Akinori Nakayama Masahiro Toide Tatsuaki Yoneda Kazushige Sakaguchi Jun Teishima Kazuhide Makiyama Takahiro Inoue Hiroshi Kitamura Kazutaka Saito Fumitaka Koga Shinji Urakami Takuya Koie Pelvic Lymphadenectomy May Not Improve Biochemical Recurrence-Free Survival in Patients with Prostate Cancer Treated with Robot-Assisted Radical Prostatectomy in Japan (The MSUG94 Group) Cancers multicenter cohort study pelvic lymph node dissection prostate cancer robot-assisted radical prostatectomy |
| title | Pelvic Lymphadenectomy May Not Improve Biochemical Recurrence-Free Survival in Patients with Prostate Cancer Treated with Robot-Assisted Radical Prostatectomy in Japan (The MSUG94 Group) |
| title_full | Pelvic Lymphadenectomy May Not Improve Biochemical Recurrence-Free Survival in Patients with Prostate Cancer Treated with Robot-Assisted Radical Prostatectomy in Japan (The MSUG94 Group) |
| title_fullStr | Pelvic Lymphadenectomy May Not Improve Biochemical Recurrence-Free Survival in Patients with Prostate Cancer Treated with Robot-Assisted Radical Prostatectomy in Japan (The MSUG94 Group) |
| title_full_unstemmed | Pelvic Lymphadenectomy May Not Improve Biochemical Recurrence-Free Survival in Patients with Prostate Cancer Treated with Robot-Assisted Radical Prostatectomy in Japan (The MSUG94 Group) |
| title_short | Pelvic Lymphadenectomy May Not Improve Biochemical Recurrence-Free Survival in Patients with Prostate Cancer Treated with Robot-Assisted Radical Prostatectomy in Japan (The MSUG94 Group) |
| title_sort | pelvic lymphadenectomy may not improve biochemical recurrence free survival in patients with prostate cancer treated with robot assisted radical prostatectomy in japan the msug94 group |
| topic | multicenter cohort study pelvic lymph node dissection prostate cancer robot-assisted radical prostatectomy |
| url | https://www.mdpi.com/2072-6694/14/23/5803 |
| work_keys_str_mv | AT sanaenamiki pelviclymphadenectomymaynotimprovebiochemicalrecurrencefreesurvivalinpatientswithprostatecancertreatedwithrobotassistedradicalprostatectomyinjapanthemsug94group AT makotokawase pelviclymphadenectomymaynotimprovebiochemicalrecurrencefreesurvivalinpatientswithprostatecancertreatedwithrobotassistedradicalprostatectomyinjapanthemsug94group AT shinebara pelviclymphadenectomymaynotimprovebiochemicalrecurrencefreesurvivalinpatientswithprostatecancertreatedwithrobotassistedradicalprostatectomyinjapanthemsug94group AT tomoyukitatenuma pelviclymphadenectomymaynotimprovebiochemicalrecurrencefreesurvivalinpatientswithprostatecancertreatedwithrobotassistedradicalprostatectomyinjapanthemsug94group AT takeshisasaki pelviclymphadenectomymaynotimprovebiochemicalrecurrencefreesurvivalinpatientswithprostatecancertreatedwithrobotassistedradicalprostatectomyinjapanthemsug94group AT yoshinoriikehata pelviclymphadenectomymaynotimprovebiochemicalrecurrencefreesurvivalinpatientswithprostatecancertreatedwithrobotassistedradicalprostatectomyinjapanthemsug94group AT akinorinakayama pelviclymphadenectomymaynotimprovebiochemicalrecurrencefreesurvivalinpatientswithprostatecancertreatedwithrobotassistedradicalprostatectomyinjapanthemsug94group AT masahirotoide pelviclymphadenectomymaynotimprovebiochemicalrecurrencefreesurvivalinpatientswithprostatecancertreatedwithrobotassistedradicalprostatectomyinjapanthemsug94group AT tatsuakiyoneda pelviclymphadenectomymaynotimprovebiochemicalrecurrencefreesurvivalinpatientswithprostatecancertreatedwithrobotassistedradicalprostatectomyinjapanthemsug94group AT kazushigesakaguchi pelviclymphadenectomymaynotimprovebiochemicalrecurrencefreesurvivalinpatientswithprostatecancertreatedwithrobotassistedradicalprostatectomyinjapanthemsug94group AT junteishima pelviclymphadenectomymaynotimprovebiochemicalrecurrencefreesurvivalinpatientswithprostatecancertreatedwithrobotassistedradicalprostatectomyinjapanthemsug94group AT kazuhidemakiyama pelviclymphadenectomymaynotimprovebiochemicalrecurrencefreesurvivalinpatientswithprostatecancertreatedwithrobotassistedradicalprostatectomyinjapanthemsug94group AT takahiroinoue pelviclymphadenectomymaynotimprovebiochemicalrecurrencefreesurvivalinpatientswithprostatecancertreatedwithrobotassistedradicalprostatectomyinjapanthemsug94group AT hiroshikitamura pelviclymphadenectomymaynotimprovebiochemicalrecurrencefreesurvivalinpatientswithprostatecancertreatedwithrobotassistedradicalprostatectomyinjapanthemsug94group AT kazutakasaito pelviclymphadenectomymaynotimprovebiochemicalrecurrencefreesurvivalinpatientswithprostatecancertreatedwithrobotassistedradicalprostatectomyinjapanthemsug94group AT fumitakakoga pelviclymphadenectomymaynotimprovebiochemicalrecurrencefreesurvivalinpatientswithprostatecancertreatedwithrobotassistedradicalprostatectomyinjapanthemsug94group AT shinjiurakami pelviclymphadenectomymaynotimprovebiochemicalrecurrencefreesurvivalinpatientswithprostatecancertreatedwithrobotassistedradicalprostatectomyinjapanthemsug94group AT takuyakoie pelviclymphadenectomymaynotimprovebiochemicalrecurrencefreesurvivalinpatientswithprostatecancertreatedwithrobotassistedradicalprostatectomyinjapanthemsug94group |